Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuron
Sponsored by Merck Sharp & Dohme Corp.
$260.6K Funding
1 People
External
Related Topics
clinical trials,
drug safety,
neuromuscular blockade,
reversal agent,
active comparator
People
Peter Lichtenthal
Principal Investigator (PI)
Anesthesiology
﹒Professor
